According to a February 17, 2026 SEC filing, DAFNA Capital Management LLC reduced its stake in iShares Biotech ETF (NASDAQ:IBB) for 34,405 shares during the fourth quarter of 2025. The value of the fund’s quarter-end IBB position decreased by $3.31 million, a figure that took into account both share sales and price movement.
Following the sale, the iShares Biotechnology ETF comprises 2.67% of DAFNA Capital’s 13F reportable assets under management.
Top five holdings after the presentation:
-
NASDAQ:RVMD: $48.15 million (11.3% of assets under management)
-
NYSEMKT:XBI: $41.03 million (9.7% of assets under management)
-
NYSEMKT:STXS: $31.47 million (7.4% of assets under management)
-
NASDAQ:ATRC: $23.63 million (5.6% of assets under management)
-
NASDAQ:CYTK: $23.57 million (5.5% of assets under management)
As of February 17, 2026, IBB shares were priced at $174.02, up 27.2% year-over-year, with a one-year alpha of 15.84 percentage points versus the S&P 500.
|
Metric |
Worth |
|---|---|
|
AUM |
8.78 billion |
|
Price (at market close 02/17/26) |
$174.02 |
|
One-year total return |
22.07% |
|
Dividend yield |
0.22% |
The iShares Biotechnology ETF offers investors targeted exposure to the biotechnology sector by tracking a specialized industry index. The ETF tracks the performance of the NASDAQ Biotechnology Index by investing at least 80% of assets in index components and substantially identical securities. Invests primarily in biotech and pharmaceutical stocks, with diversified exposure across major industry constituents.
The fund employs a passive investment approach, allocating the majority of assets to companies within the NASDAQ Biotechnology Index and maintaining the flexibility to use derivatives for portfolio management. It is structured as a non-diversified ETF, focused on efficient index replication and liquidity management.
Its scale and liquidity offer institutional investors efficient access to a wide range of biotechnology stocks, supporting portfolio diversification and sector strategies.
The iShares Biotechnology ETF (IBB) offers exposure to the biotechnology sector through a market cap-weighted portfolio focused on large commercial-stage companies with approved products and established pipelines. This approach emphasizes industry leaders and reduces reliance on higher-risk, early-stage companies.
IBB’s performance is primarily driven by large-cap biotech earnings, product results, project progress and regulatory decisions. Since the fund has a large number of companies, a small number of companies account for the majority of the returns. Although established companies may reduce volatility compared to equally weighted biotech funds, the sector remains sensitive to interest rates and investors’ risk appetite, which affect the valuation of growth-oriented healthcare stocks.